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Objective: Current data are limited on the course of type 1 diabetes (T1D) in children and 
adolescents through the first few years of diabetes. The Pediatric Diabetes Consortium T1D New 
Onset (NeOn) Study was undertaken to prospectively assess natural history and clinical 
outcomes in children treated at 7 US diabetes centers from the time of diagnosis. This paper 
describes clinical outcomes in the T1D NeOn cohort during the first 3 years post-diagnosis.  
Results: 1048 participants (mean age 9.2 years, 49% female, 65% non-Hispanic White) were 
enrolled between July 2009 and April 2011. Mean HbA1c (±SD) was 7.2% (55 mmol/mol) at 3 
months, followed by a progressive rise to 8.4% (68 mmol/mol) at 36 months post-diagnosis, with 
only 30% of participants achieving target HbA1c<7.5% (58 mmol/mol). The percentage of 
participants in partial remission estimated by insulin dose adjusted HbA1c [HbA1c % + (4 x 
insulin dose unit/kg/24 h)] d9 sharply declined from 23% at 12 months to 7% at 36 months. The 
percentage of participants developing diabetic ketoacidosis (DKA) was 1% in the first year after 
diagnosis, increasing to 6% in year 2 and year 3.  
Conclusions: These results demonstrate the gradual decline in glycemic control due to waning 
residual endogenous insulin secretion with increasing duration of T1D in children and 
adolescents. These data indicate the need to translate recent advances in automated insulin 
delivery, new insulin analogs and adjunctive pharmacologic agents into novel treatment 
strategies to maintain optimal glycemic control even early in the course of T1D. 
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It has long been recognized that optimal metabolic control is much easier to achieve 
during the partial remission (or honeymoon) period in youth with new-onset T1D than later in 
the course of the disease. Moreover, the Diabetes Control and Complications Trial (DCCT) 
demonstrated that intensive treatment of T1D could slow the loss of residual ² -cell function, 
resulting in lower HbA1c levels and a reduced risk of severe hypoglycemia (1). The recent 
DirecNet/TrialNet Metabolic Control Study (2, 3) and the European Pediatric Onset Study (4) 
indicate that the highest c-peptide values and lowest HbA1c levels are observed in youth with 
newly diagnosed T1D during the first 6 months of treatment, whereas c-peptide levels begin to 
decline and HbA1c levels increase over the subsequent 6 months (2-6).   
Outside of the relatively small numbers of participants enrolled in clinical trials of early 
use of insulin pumps and continuous glucose monitors, the time course and consequences of loss 
of residual ² -cell function in youth with new onset T1D in clinical practice settings has not been 
well established. A clear understanding of the waning of the honeymoon phase of T1D in 
children and adolescents would facilitate the design of clinical trials of new therapies aimed at 
preserving residual ² -cell function, as well as enhancing vigilance in diabetes management 
during this critical phase of transition (7). In order to fill gaps in knowledge regarding the natural 
history of the honeymoon phase of T1D in children and adolescents, the Pediatric Diabetes 
Consortium (PDC) enrolled pediatric patients who had been newly diagnosed with T1D into the 
New Onset (NeOn) Study (5). Clinical outcomes in the NeOn cohort during the first year of 
treatment were similar to those in recent clinical trials, in that the lowest HbA1c levels were 
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observed between 3-6 months post-diagnosis, with a progressive rise in HbA1c values at 9 and 
12 months (5). In this paper, we describe the results of follow-up evaluations in the PDC T1D 
NeOn Study cohort after the first year following diagnosis through up to 3 years of follow up.  





The PDC enrolled 1,048 patients diagnosed with T1D between July 2009 and April 2011. 
The protocol was approved by the Institutional Review Board (IRB) at each of the 7 participating 
pediatric diabetes treatment centers in the US. To be eligible for enrollment in the study, patients 
had to be <19 years of age and managed at one of the 7 participating PDC centers within 3 
months of diagnosis. Informed consent was obtained from participants 18 years of age and from 
parents of those less than 18 years of age; assent was obtained from participants <18 years of age 
as required by local IRB regulations. A detailed description of PDC, the design of the study, and 
data collection methods have been published previously (5).  
Data Collection 
Demographic, socioeconomic and clinical data were collected from medical records and 
from interviews with the participant and/or parent. Follow-up visits, including screening and 
diagnosis of thyroid and celiac disease screening and diagnosis were completed per usual care 
and all visits were entered in the standardized electronic case report forms for the study. Severe 
hypoglycemic (SH) events were defined as episodes of hypoglycemia that required the assistance 
of another person to treat with oral carbohydrate, intravenous glucose, or intramuscular 
glucagon, due to altered consciousness or seizure.  Diabetic ketoacidosis (DKA) events were 
defined by the DCCT criteria of pH <7.3 or HCO3 <15mEq/l with hyperglycemia and treatment 
in a healthcare facility.  HbA1c levels were measured by the DCA immunoassay method 
(Siemens Health Care) at all of the centers.  The Insulin Dose Adjusted HbA1c (IDAA1c) is a 
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validated measure to determine beta cell reserve in patients with T1D. IDAA1c values d9.0 
correspond to a predicted stimulated C-peptide >300 pmol/l and it was defined as HbA1c % + [4 
x insulin dose (units per kg per 24 h)] (8).   
Statistical Analyses 
Clinical characteristics of the participants were presented at the following time points: 
diagnosis (0-14 days), 3 months (1.5-4.5 months), 6 months (4.5-7.5 months), 12 months (10.5-
15 months), 24 months (21-27 months) and 36 months (33-39 months) from diagnosis. A 3-year 
completer was defined as a participant who had a visit between 33-39 months from diagnosis. 
Body mass index (BMI) was calculated from the height and weight measurements closest to each 
target time point.  BMI percentile and standard deviation score for age and gender were 
calculated using the 2000 CDC population growth chart data (9).  
Descriptive statistics included means, SD, median, interquartile range, and proportions 
when appropriate. Correlations between frequency of self-monitoring of blood glucose (SMBG) 
and HbA1c were computed using Spearman correlation, and correlations for HbA1c at different 
visits were assessed by Pearson correlation. Repeated measures least square models were used to 
assess whether HbA1c and IDAA1c differed by DKA and SH status over time. Interaction 
between DKA/SH status with visit time was also evaluated. Since the difference in HbA1c 
between DKA and no DKA subgroups was different by visit, t-test was used to compare HbA1c 
between DKA vs. no DKA at each visit, and the results were presented separately by visit. A 
repeated measures least square model was also used to assess the association between HbA1c 
and obesity. Life-table method was used to calculate cumulative event rate for comorbidities. 
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Statistical analyses were conducted using SAS 9.4 statistical software (SAS Institute Inc., Cary, 
North Carolina).   




The mean age of the cohort at diagnosis was 9.2 years (range 0.7 to18.8 years); 49% were 
female; 65% were non-Hispanic White, 21% were Hispanic and 8% were non-Hispanic Black 
(Table 1). The majority of participants had health insurance, parents with a college degree or 
above, and a family income greater than $50,000.  A comparison of baseline factors in 3-year 
completers vs. non-completers is shown in Supplemental Table 1, and clinical outcome measures 
among 3-year completers are reported in Supplemental Table 2. 
Glycemic Control of T1D (Table 2 and Figure 1) 
Nadir mean HbA1c (±SD) was 7.2 (±1.1) to 7.3 (±1.4) % [55 (±12) to 56 (±15) 
mmol/mol] at 3 and 6 months, followed by a progressive rise to 8.4 (±1.6) % [68 (±18) 
mmol/mol] at 36 months post-diagnosis. The highest HbA1c levels at 36 months were seen in 
adolescents (Table 2). Sixty-one percent of participants achieved target HbA1c levels <7.5% (58 
mmol/mol) at 3 and 6 months but this fell to only 30% by 36 months. HbA1c levels were 
significantly correlated among different visits (Figure 3), with Pearson correlation coefficient 
(95% confidence interval) of 0.68 (0.64, 0.71), 0.56 (0.50, 0.62) and 0.74 (0.69, 0.77) for HbA1c 
at 24 months vs. 12 months, 36 months vs. 12 months and 36 months vs. 24 months, 
respectively. 
Diabetes Management 
An insulin pump was being used by 46% of participants at 24 months and 48% at 36 
months. Only 2-4% of participants reported using a continuous glucose monitor between 6 and 
36 months. The median self-reported number of self-monitored blood glucose (SMBG) tests per 
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day remained consistent at 5 per day through 36 months (Table 2). There was a significant 
association between HbA1c and the daily number of SMBG tests with a correlation that 
increased from 12 months to 36 months (r = -0.27, -0.24, -0.33 for 12, 24 and 36 months 
respectively, all p-values<0.001). 
IDDA1c 
As shown in Table 2, there also was a progressive increase in IDAA1c that reflected the 
increases in HbA1c values and total daily insulin doses over the course of the study.  
Consequently, the percentage of participants who were in partial remission, as indicated by 
IDAA1c values d9.0, fell from 49% at 3 months to 23% at 12 months and to only 7% at 36 
months, respectively. The rate of decline in C-peptide estimated by the IDAA1c was lower in 
younger participants. 
BMI 
The median (interquartile range) BMI percentile was 50% (14−78%) at the time of 
diagnosis, increased to 69% (44−88%) at 6 months, and then remained relatively constant 
throughout the first three years of T1D (Figure 2).  BMI percentile was inversely associated with 
HbA1c (P<0.001) after adjusting for visit time. 
Severe Hypoglycemia and Diabetic Ketoacidosis 
During the first year of T1D, SH episodes were reported by 2% of participants.  By 24 
and 36 months, the percentages of participants with SH episodes in the prior 12 months were 3% 
and 4%, respectively. The percentage of participants who reported more than one episode of SH 
within the prior 12 months was only 1% at 36 months.  DKA occurred in 1% of participants 
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during the first year of T1D, not including episodes at presentation. By 24 and 36 months, the 
percentages of participants with DKA in the prior 12 months increased considerably to 6% and 
6% (Table 2).  Mean HbA1c levels were significantly higher among those with a DKA event 
than those without a DKA event at 12 months, 24 months and 36 months (all p-values<0.001), 
with mean A1c 9.4 ± 1.6% vs. 7.8 ± 1.4% (79 ± 17 mmol/mol vs. 61 ± 16 mmol/mol), 9.3 ± 
2.3% vs. 8.0 ± 1.4% (79 ± 25 mmol/mol vs. 64 ± 15 mmol/mol) and 9.3 ± 1.9% vs. 8.3 ± 1.6% 
(79 ± 21 mmol/mol vs. 67 ± 17 mmol/mol) among the DKA vs. no DKA group at 12, 24, and 36 
months respectively. Those participants with a DKA event also had significantly higher IDAA1c 
than those without a DKA event after adjusting for visit time (P=0.002). There was no significant 
difference in either HbA1c or IDAA1c levels between those participants with a SH event and 
those without a SH event after adjusting for visits (P=0.18 and 0.64, respectively). 
Comorbidities diagnosed after initial screening evaluation at diagnosis 
 As shown in Table 3, the cumulative rate for diagnosis of thyroid disease slightly 
increased from 2% during the first year after diagnosis to 3% after three years. While only <1% 
of participants had been diagnosed with psychiatric disorders and 2% had been diagnosed with 
celiac disease during the first year of diabetes, the cumulative event rate of psychiatric disorders 
and celiac disease increased to 2% and 5% respectively after three years of T1D duration.   




An important finding of this study is that the rise in HbA1c levels, increases in total daily 
insulin doses and waning of the partial remission period that were observed between 6 and 12 
months after the diagnosis of T1D in this cohort (5) continued for the next 2 years at slower 
rates, but accompanied with a steep increase in number of episodes of DKA. While the pattern of 
glycemic control changes, namely the timing of nadir HbA1c and the trajectory of rise in HbA1c, 
is similar to those reported during the first 12 months of new onset patients in the DirecNet-
TrialNet Metabolic Control Study (2, 3) and during 24 months of follow-up of the Pediatric 
Onset Study in Europe (4), HbA1c levels were higher in the NeOn Study cohort at each time 
point. These differences may be due to the difference in the frequency and intensity of contact 
with participants in clinical trials versus patients in clinical practice, but could also be due to 
differences in patients who participate in clinical trials versus those who do not. It is noteworthy 
that patients and caregivers responded to the increasing challenges in managing their diabetes by 
maintaining a high frequency of blood glucose monitoring and increasing use of insulin pumps 
over time.  
While c-peptide responses to mixed meal tolerance tests were not measured in the NeOn 
Study, the IDAA1C developed and validated by Mortensen and colleagues, was used as a 
surrogate measure of residual ² -cell function (8). Those investigators demonstrated that an 
IDAA1C value d9.0 predicts peak meal-stimulated c-peptide levels that are almost always >300 
pmol/l. Similar c-peptide responses can be seen in youth with T1D with IDAA1C values 
between 9.0 and 10.0, albeit less frequently. Although there is data supporting the use of 
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IDAA1c, the IDAA1c has some limitations. The data were derived from a non-US population 
with a different genetic background. The stimulated C-peptide cut-off level as a measure of 
residual ² -cell function was even higher than the cut-off level that was used to define absolute 
insulin deficiency in the DCCT cohort (C-peptide <200pmol/L ) despite the fact that, unlike the 
DCCT patient population, subjects younger than 13 years of age were enrolled into the study by 
Mortensen. Hence, the IDAA1c might not be applicable to assess the ² -cell reserve for younger 
patients who tend to have lower C-Peptide levels as compared to older people with new onset 
T1D. Moreover, the DPV partial remission analysis demonstrated younger children are 
significantly less likely to experience partial remission (10). The data points on the regression 
analysis graph published in Mortensen’s paper depict many subjects without partial remission (8) 
who have stimulated C-peptide levels >300pg/mL. The possible underestimation of partial 
remission and a faster rate of increase in older versus younger subjects could be driven by the 
higher insulin dose requirement per kilogram weight commonly observed in adolescent patients 
during puberty (11). Our finding that the proportion of participants with IDDA1c values <9.0 
was as high as 23% at 12 months but fell to 12% and 7% at 24 and 36 months suggests that 
future ² -cell preservation studies may have to be extended to 24-36 months in order to detect 
differences in C-peptide responses between experimental and control groups.  
 It was somewhat surprising that the reported frequency of SH episodes did not increase 
with waning of the partial remission phase during the first 3 years of diabetes treatment. One 
possible explanation is that the IDAA1c might not be a sensitive measure to determine the risk 
for severe hypoglycemia in this patient population. Unlike SH, the number of episodes of DKA 
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did rise in parallel to the rise in HbA1c levels, a finding similar to that in pediatric patients with 
longer diabetes duration enrolled in the T1D Exchange Clinic Registry (12).   
T1D Exchange Registry data indicate that youth with T1D have not been spared from the 
epidemic of obesity that afflicts so many non-diabetic children (13). Thus, the initial increase in 
BMI to >60th percentile at 6 months is likely due to the regain of weight lost prior to the 
diagnosis of diabetes, whereas, the lack of any substantial change in BMI after 6 months is 
evidence against a major effect of insulin treatment itself.  
It is not uncommon for associated autoimmune diseases to develop after the diagnosis of 
T1D, and this explains the increasing prevalence of thyroid and celiac disease over time. The 
increasing prevalence of psychiatric disorders probably represents the increasing age of the 
cohort as participants entered adolescence, increased awareness of mental health issues (14) as 
well as the longer duration of the disease.  
There are a few limitations of the PDC NeOn Study. The study was not designed as a 
population-based study, since all of the participants enrolled into the study were being followed 
in academic pediatrics diabetes centers within 3 months of diagnosis. While this factor raises a 
concern about representativeness of our findings, the majority of pediatric patients with T1D in 
the U.S. are managed by pediatric diabetologists as common practice, unlike the adult patient 
population whose care is often shared by specialists and primary care givers (15).  Maximum 
amount of possible follow up was incomplete for 29% of the cohort; however, baseline 
characteristics appeared quite similar between those with complete versus incomplete follow up, 
suggesting that this is not a source of bias.  
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            The findings of the NeOn Study underscore the importance of maintaining a commitment 
by patients and parents of children with T1D to intensive insulin therapy during the transition 
period out of the partial remission phase in order to keep HbA1c levels within the target range. 
Unfortunately, only about 30% of participants were able achieve this goal after the first 2 years 
of T1D despite their high median income and well educated background.  The percentage of 
pediatric patients who are within target glycemic range has been reported to be even lower, based 
on a recently published database study (16). Nevertheless, improvements in accuracy and ease of 
use of CGM devices and the introduction of integrated sensor-augmented pump systems provide 
new and relatively untapped opportunities for achieving optimal glycemic control in a larger 
proportion of youth with T1D (17), including those recently diagnosed. As the DCCT has shown, 
getting a larger proportion of patients to target HbA1c levels as early in the course of the disease 
as possible will have long lasting benefits in reducing the risk of future vascular complications 
(1, 18).  
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Table 1: Characteristics at Diagnosis (N=1048a) 
 # % 
Age   
<5 years 199 19% 
5−<12 years 568 54% 
12−<19years 281 27% 
Mean ± SD 9.2 ± 4.2 
Range 0.7 – 18.8 
Gender   
Female 513 49% 
Race/Ethnicity   
Non-Hispanic White 671 65% 
Hispanic or Latino 216 21% 
Black/African American 81 8% 
Other/Multiple Race 59 6% 
Health Insurance   
Private  681 66% 
Children’s Health Plan or Other Government 302 29% 
Military 19 2% 
None 23 2% 
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Parent Education   
High School or Less 291 34% 
Associate Degree 121 14% 
BS/BA 245 29% 
MS/MA/Professional Degree 202 24% 
Family Income   
<$25,000 101 14% 
$25,000-$49,999 133 19% 
$50,000-$74,999 112 16% 
$75,000-$99,999 101 14% 
e$100,000 255 36% 
a. Number of participants with missing data: race/ethnicity (21), health insurance (23), parent education (189), and 
family income (346). 
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Table 2: Clinical Characteristics by Completed Follow-up Visit 
  Diagnosis 3 Months 6 Months 12 Months 24 Months 36 Months 
 N=1048b N=841b N=838b N=897b N=822b N=607b 
Pump Use 12 (1%) 76 (9%) 141 (17%) 309 (34%) 376 (46%) 293 (48%) 
  N=784b N=786b N=847b N=481b N=356b 
CGM Use NA 2% 3% 2% 4% 4% 
  N=507b N=495b N=517b N=417b N=322b 
Self Blood Glucose 
Monitoring (# tests 
/ day)  
median (IQR) 
NA 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 7) 5 (4, 7) 
 
N=980b N=788b N=789b N=859b N=789b N=579b 
HbA1c  
(% [mmol/mol]) 
mean ± SD  
 
11.5 ± 2.3 
[102 ± 25] 
7.2 ± 1.1 
[55 ± 12] 
7.3 ± 1.4 
[56 ± 15] 
7.8 ± 1.5 
[62 ± 16] 
8.1 ± 1.4 
[65 ± 16] 
8.4 ± 1.6 
[68 ± 18] 
Age <5 years 
10.5 ± 2.0 
[91 ± 21] 
7.8 ± 1.1 
[62 ± 12] 
7.9 ± 1.2 
[62 ± 14] 
7.9 ± 1.1 
[62 ± 12] 
7.9 ± 1.0 
[63 ± 11] 
8.0 ± 1.2 
[64 ± 13] 
5−<12 years 
11.5 ± 2.3 
[102 ± 25] 
7.1 ± 1.0 
[54 ± 11] 
7.2 ± 1.2 
[55 ± 13] 
7.8 ± 1.3 
[62 ± 14] 
8.1 ± 1.4 
[65 ± 15] 
8.4 ± 1.5 
[68 ± 17] 




12.1 ± 2.4 
[109 ± 27] 
7.0 ± 1.2 
[53 ± 13] 
7.0 ± 1.7 
[53 ± 18] 
7.7 ± 2.0 
[61 ± 21] 
8.1 ± 1.8 
[65 ± 20] 
8.6 ± 2.0 
[71 ± 22] 
HbA1c<7.5% (58 
mmol/mol) 
3% 61% 61% 45% 34% 30% 
  N=747b N=611b N=708b N=741b N=539b 
HbA1c Change (% 
[mmol/mol]) 
mean ± SD  
 
NA 
-4.3 ± 2.5 
[-47 ± 28] 
+0.1 ± 1.1 
[+1 ± 12] 
+0.5 ± 1.2 
[+5 ± 13] 
+0.3 ± 1.1 
[+4 ± 12] 
+0.2 ± 1.1 
[+2 ± 12] 
  N=691b N=713b N=795b N=442b N=316b 
Total Insulin 
(u/day/kg) 
mean ± SD  
NA 0.5 ± 0.3 0.5 ± 0.3 0.7 ± 0.3 0.8 ± 0.4 1.0 ± 0.6 
Basal  NA 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.2 
Bolus  NA 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.4 0.6 ± 0.5 
  N=669b N=678b N=767b N=421b N=296b 
IDAA1c (%)  
mean ± SD  
NA 9.3 ± 1.8 9.4 ± 2.1 10.5 ± 2.2 11.3 ± 2.4 12.2 ± 2.9 
IDAA1cd9.0% NA 49% 48% 23% 12% 7% 
Age<5 years NA 35% 31% 22% 13% 10% 
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5−<12 years NA 52% 52% 21% 11% 3% 
12−<19 years NA 53% 54% 28% 11% 14% 
   N=473b N=581b N=376b N=188b 
IDAA1c Change 
(%) mean ± SD  
NA NA +0.2 ± 1.6 +0.9 ± 1.7 +0.9 ± 2.0 +1.2 ± 2.8 
    N=1044b N=727b N=584b 
SH in prior yeara NA NA NA 2% 3% 4% 
# SH events >1 in 
prior yeara 
NA NA NA <1% <1% 1% 
DKA reported in 
prior yeara 
NA NA NA 1%c 6% 6% 
# DKA events >1 in 
prior yeara 
NA NA NA <1%c 1% 1% 
a. Participant/parent was asked at the visit whether an event had occurred in the previous 12 months. 
b. N varies due to missing data at the particular time point. 
c. DKA events at diagnosis were excluded.
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Table 3 Comorbidities after T1D Diagnosis (N=1044a) 
Diabetes Duration, 
years 





N Cumulative Event 
Rate 
1 16 2% 19 2% 7 <1% 
2 7 2% 14 3% 10 2% 
3 5 3% 11 5% 3 2% 
Total 28  44  20  
a- Excludes 4 participants with no visit available after enrollment 
b- Includes Graves’ disease, Hashimoto’s and any other thyroiditis 
c- Includes bipolar, anxiety, depression, disruptive behavior, central pain syndrome  
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Supplemental Table 1: Comparing Characteristics of 3-Year Completers and Non-
completers 




Age   
<5 years 108 (18%) 91 (21%) 
5−<12 years 356 (59%) 212 (48%) 
12−<19years 143 (24%) 138 (31%) 
Mean ± SD 9.0 ± 3.9 9.5 ± 4.6 
Range 0.8 – 18.2 0.7 – 18.8 
Gender   
Female 305 (50%) 208 (47%) 
Race/Ethnicity   
Non-Hispanic White 387 (65%) 284 (66%) 
Hispanic or Latino 122 (21%) 94 (22%) 
Black/African American 45 (8%) 36 (8%) 
Other/Multiple Race 40 (7%) 19 (4%) 
Health Insurance   
Private  396 (66%) 285 (67%) 
Children’s Health Plan or Other 176 (29%) 126 (29%) 




Military 13 (2%) 6 (1%) 
None 12 (2%) 11 (3%) 
Parent Education   
High School or Less 164 (33%) 127 (35%) 
Associate Degree 66 (13%) 55 (15%) 
BS/BA 142 (29%) 103 (28%) 
MS/MA/Professional Degree 119 (24%) 83 (23%) 
Family Income   
<$25,000 61 (15%) 40 (14%) 
$25,000-$49,999 71 (17%) 62 (21%) 
$50,000-$74,999 65 (16%) 47 (16%) 
$75,000-$99,999 64 (16%) 37 (13%) 
e$100,000 146 (36%) 109 (37%) 
a. Completers defined as participants who had visit within ±3 months of 36-month target date. 
b. Number of participants with missing data (completers/non-completers): race/ethnicity (13/8), health insurance 
(10/13), parent education (116/73), and family income (200/146).   
This article is protected by copyright. All rights reserved.
 30 
 
Supplemental Table 2: Clinical Characteristics among 3-Year Completersa 
  Diagnosis 3 Months 6 Months 12 Months 24 Months 36 Months 
 N=607c N=490c N=520c N=571c N=565c N=607c 
Pump Use <1% 7% 15% 34% 45% 48% 
  N=452c N=485c N=538c N=354c N=356c 
CGM Use NA 1% 2% 2% 4% 4% 
  N=314c N=323c N=345c N=304c N=322c 
Self Blood Glucose 
Monitoring (# tests 
/ day)  
median (IQR) 
NA 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 7) 5 (4, 7) 
 
N=578c N=462c N=491c N=551c N=546c N=579c 
HbA1c  
(% [mmol/mol]) 
mean ± SD  
 
11.5 ±2.4 
[102 ± 26] 
7.2 ± 1.1 
[55 ± 12] 
7.2 ±1.3 
[55 ± 14] 
7.7 ±1.4 
[61 ± 15] 
8.1 ± 1.4 
[65 ± 15] 
8.4 ± 1.6 
[68 ± 18] 
Age <5 years 
10.5 ± 2.1 
[91 ± 23] 
7.8 ± 1.2 
[62 ± 13] 
7.9 ± 1.2 
[62 ± 13] 
7.9 ± 1.1 
[63 ± 12] 
8.0 ± 1.0 
[64 ± 11] 
8.0 ± 1.2 
[64 ± 13] 
5−<12 years 
11.6 ± 2.3 
[103 ± 25] 
7.1 ± 1.0 
[54 ± 11] 
7.2 ± 1.2 
[55 ± 14] 
7.7 ± 1.3 
[61 ± 14] 
8.1 ± 1.3 
[65 ± 15] 
8.4 ± 1.5 
[68 ± 17] 




12.2 ± 2.4 
[110 ± 26] 
6.8 ± 1.1 
[51 ± 12] 
6.7 ± 1.3 
[50 ± 14] 
7.5 ± 1.7 
[58 ± 18] 
8.0 ± 1.7 
[64 ± 18] 
8.6 ± 2.0 
[71 ± 22] 
HbA1c<7.5% (58 
mmol/mol) 
3% 64% 64% 47% 32% 30% 
  N=447c N=374c N=461c N=514c N=539c 
HbA1c Change  
(% [mmol/mol]) 
mean ± SD  
 
NA 
-4.3 ± 2.7 
[-47 ± 29] 
+0.1 ± 1.0 
[+1 ± 11] 
+0.4 ± 1.2 
[+5 ± 13] 
+0.3 ± 1.1 
[+4 ± 12] 
+0.2 ± 1.1 
[+2 ± 12] 
  N=403c N=448c N=511c N=327c N=316c 
Total Insulin 
(u/day/kg)  
mean ± SD 
NA 0.5 ± 0.3 0.5 ± 0.3 0.6 ± 0.3 0.8 ± 0.4 1.0 ± 0.6 
Basal  NA 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 
Bolus  NA 0.2 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.3 0.6 ± 0.5 
  N=390c N=426c N=494c N=317c N=296c 
IDAA1c (%) 
mean ± SD  
NA 9.3 ± 1.7 9.3 ± 1.9 10.4 ± 2.1 11.2 ± 2.2 12.2 ± 2.9 
IDAA1cd9.0% NA 50% 50% 23% 12% 7% 
Age <5 years NA 35% 29% 20% 16% 10% 
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5−<12 years NA 50% 54% 23% 10% 3% 
12−<19 years NA 63% 58% 28% 11% 14% 
   N=291c N=378c N=285c N=188c 
IDAA1c Change 
(%) mean ± SD  
NA NA +0.2 ± 1.4 +1.0 ± 1.6 +0.9 ± 1.7 +1.2 ± 2.8 
    N=607c N=462c N=532c 
SH in prior yearb NA NA NA 2% 4% 4% 
# SH events >1 in 
prior yearb 
NA NA NA <1% <1% 1% 
DKA reported in 
prior yearb 
NA NA NA 1%d 5% 6% 
# DKA events >1 
in prior yearb 
NA NA NA 0% 1% 1% 
a – 3-year completer is defined as participants who had visit within ±3 months of 36-month target date.  
b – Participant/parent was asked at the visit whether an event had occurred in the previous 12 months. 
c – N varies due to missing data at the particular time point. 
d – DKA events at diagnosis were excluded.




Figure 1: HbA1c by T1D Duration 
The bottom and the top of each box plot denote the 25th and 75th percentiles.  Horizontal line 
inside each box plot denotes the median, and the dot denotes the mean. 
Figure 2: BMI Percentile by T1D Duration 
The bottom and the top of each box plot denote the 25th and 75th percentiles.  Horizontal line 
inside each box denotes the median, and the dot denotes the mean. 
Figure 3: Scatter Plots for HbA1c at Different Visits 
A) HbA1c at 24 months vs. 12 months; B) HbA1c at 36 months vs. 12 months; C) HbA1c at 36 
months vs. 24 months. 
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Objective: Current data are limited on the course of type 1 diabetes (T1D) in children and 
adolescents through the first few years of diabetes. The Pediatric Diabetes Consortium T1D New 
Onset (NeOn) Study was undertaken to prospectively assess natural history and clinical 
outcomes in children treated at 7 US diabetes centers from the time of diagnosis. This paper 
describes clinical outcomes in the T1D NeOn cohort during the first 3 years post-diagnosis.  
Results: 1048 participants (mean age 9.2 years, 49% female, 65% non-Hispanic White) were 
enrolled between July 2009 and April 2011. Mean HbA1c (±SD) was 7.2% (55 mmol/mol) at 3 
months, followed by a progressive rise to 8.4% (68 mmol/mol) at 36 months post-diagnosis, with 
only 30% of participants achieving target HbA1c<7.5% (58 mmol/mol). The percentage of 
participants in partial remission estimated by insulin dose adjusted HbA1c [HbA1c % + (4 x 
insulin dose unit/kg/24 h)] d9 sharply declined from 23% at 12 months to 7% at 36 months. The 
percentage of participants developing diabetic ketoacidosis (DKA) was 1% in the first year after 
diagnosis, increasing to 6% in year 2 and year 3.  
Conclusions: These results demonstrate the gradual decline in glycemic control due to waning 
residual endogenous insulin secretion with increasing duration of T1D in children and 
adolescents. These data indicate the need to translate recent advances in automated insulin 
delivery, new insulin analogs and adjunctive pharmacologic agents into novel treatment 
strategies to maintain optimal glycemic control even early in the course of T1D. 
Keywords: diabetes, children, type 1, HbA1c or glycemic control   




It has long been recognized that optimal metabolic control is much easier to achieve 
during the partial remission (or honeymoon) period in youth with new-onset T1D than later in 
the course of the disease. Moreover, the Diabetes Control and Complications Trial (DCCT) 
demonstrated that intensive treatment of T1D could slow the loss of residual ² -cell function, 
resulting in lower HbA1c levels and a reduced risk of severe hypoglycemia (1). The recent 
DirecNet/TrialNet Metabolic Control Study (2, 3) and the European Pediatric Onset Study (4) 
indicate that the highest c-peptide values and lowest HbA1c levels are observed in youth with 
newly diagnosed T1D during the first 6 months of treatment, whereas c-peptide levels begin to 
decline and HbA1c levels increase over the subsequent 6 months (2-6).   
Outside of the relatively small numbers of participants enrolled in clinical trials of early 
use of insulin pumps and continuous glucose monitors, the time course and consequences of loss 
of residual ² -cell function in youth with new onset T1D in clinical practice settings has not been 
well established. A clear understanding of the waning of the honeymoon phase of T1D in 
children and adolescents would facilitate the design of clinical trials of new therapies aimed at 
preserving residual ² -cell function, as well as enhancing vigilance in diabetes management 
during this critical phase of transition (7). In order to fill gaps in knowledge regarding the natural 
history of the honeymoon phase of T1D in children and adolescents, the Pediatric Diabetes 
Consortium (PDC) enrolled pediatric patients who had been newly diagnosed with T1D into the 
New Onset (NeOn) Study (5). Clinical outcomes in the NeOn cohort during the first year of 
treatment were similar to those in recent clinical trials, in that the lowest HbA1c levels were 
observed between 3-6 months post-diagnosis, with a progressive rise in HbA1c values at 9 and 
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12 months (5). In this paper, we describe the results of follow-up evaluations in the PDC T1D 
NeOn Study cohort after the first year following diagnosis through up to 3 years of follow up.  





The PDC enrolled 1,048 patients diagnosed with T1D between July 2009 and April 2011. 
The protocol was approved by the Institutional Review Board (IRB) at each of the 7 participating 
pediatric diabetes treatment centers in the US. To be eligible for enrollment in the study, patients 
had to be <19 years of age and managed at one of the 7 participating PDC centers within 3 
months of diagnosis. Informed consent was obtained from participants 18 years of age and from 
parents of those less than 18 years of age; assent was obtained from participants <18 years of age 
as required by local IRB regulations. A detailed description of PDC, the design of the study, and 
data collection methods have been published previously (5).  
Data Collection 
Demographic, socioeconomic and clinical data were collected from medical records and 
from interviews with the participant and/or parent. Follow-up visits, including screening and 
diagnosis of thyroid and celiac disease screening and diagnosis were completed per usual care 
and all visits were entered in the standardized electronic case report forms for the study. Severe 
hypoglycemic (SH) events were defined as episodes of hypoglycemia that required the assistance 
of another person to treat with oral carbohydrate, intravenous glucose, or intramuscular 
glucagon, due to altered consciousness or seizure.  Diabetic ketoacidosis (DKA) events were 
defined by the DCCT criteria of pH <7.3 or HCO3 <15mEq/l with hyperglycemia and treatment 
in a healthcare facility.  HbA1c levels were measured by the DCA immunoassay method 
(Siemens Health Care) at all of the centers.  The Insulin Dose Adjusted HbA1c (IDAA1c) is a 
validated measure to determine beta cell reserve in patients with T1D. IDAA1c values d9.0 
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correspond to a predicted stimulated C-peptide >300 pmol/l and it was defined as HbA1c % + [4 
x insulin dose (units per kg per 24 h)] (8).   
Statistical Analyses 
Clinical characteristics of the participants were presented at the following time points: 
diagnosis (0-14 days), 3 months (1.5-4.5 months), 6 months (4.5-7.5 months), 12 months (10.5-
15 months), 24 months (21-27 months) and 36 months (33-39 months) from diagnosis. A 3-year 
completer was defined as a participant who had a visit between 33-39 months from diagnosis. 
Body mass index (BMI) was calculated from the height and weight measurements closest to each 
target time point.  BMI percentile and standard deviation score for age and gender were 
calculated using the 2000 CDC population growth chart data (9).  
Descriptive statistics included means, SD, median, interquartile range, and proportions 
when appropriate. Correlations between frequency of self-monitoring of blood glucose (SMBG) 
and HbA1c were computed using Spearman correlation, and correlations for HbA1c at different 
visits were assessed by Pearson correlation. Repeated measures least square models were used to 
assess whether HbA1c and IDAA1c differed by DKA and SH status over time. Interaction 
between DKA/SH status with visit time was also evaluated. Since the difference in HbA1c 
between DKA and no DKA subgroups was different by visit, t-test was used to compare HbA1c 
between DKA vs. no DKA at each visit, and the results were presented separately by visit. A 
repeated measures least square model was also used to assess the association between HbA1c 
and obesity. Life-table method was used to calculate cumulative event rate for comorbidities. 
Statistical analyses were conducted using SAS 9.4 statistical software (SAS Institute Inc., Cary, 
North Carolina).   




The mean age of the cohort at diagnosis was 9.2 years (range 0.7 to18.8 years); 49% were 
female; 65% were non-Hispanic White, 21% were Hispanic and 8% were non-Hispanic Black 
(Table 1). The majority of participants had health insurance, parents with a college degree or 
above, and a family income greater than $50,000.  A comparison of baseline factors in 3-year 
completers vs. non-completers is shown in Supplemental Table 1, and clinical outcome measures 
among 3-year completers are reported in Supplemental Table 2. 
Glycemic Control of T1D (Table 2 and Figure 1) 
Nadir mean HbA1c (±SD) was 7.2 (±1.1) to 7.3 (±1.4) % [55 (±12) to 56 (±15) 
mmol/mol] at 3 and 6 months, followed by a progressive rise to 8.4 (±1.6) % [68 (±18) 
mmol/mol] at 36 months post-diagnosis. The highest HbA1c levels at 36 months were seen in 
adolescents (Table 2). Sixty-one percent of participants achieved target HbA1c levels <7.5% (58 
mmol/mol) at 3 and 6 months but this fell to only 30% by 36 months. HbA1c levels were 
significantly correlated among different visits (Figure 3), with Pearson correlation coefficient 
(95% confidence interval) of 0.68 (0.64, 0.71), 0.56 (0.50, 0.62) and 0.74 (0.69, 0.77) for HbA1c 
at 24 months vs. 12 months, 36 months vs. 12 months and 36 months vs. 24 months, 
respectively. 
Diabetes Management 
An insulin pump was being used by 46% of participants at 24 months and 48% at 36 
months. Only 2-4% of participants reported using a continuous glucose monitor between 6 and 
36 months. The median self-reported number of self-monitored blood glucose (SMBG) tests per 
day remained consistent at 5 per day through 36 months (Table 2). There was a significant 
association between HbA1c and the daily number of SMBG tests with a correlation that 
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increased from 12 months to 36 months (r = -0.27, -0.24, -0.33 for 12, 24 and 36 months 
respectively, all p-values<0.001). 
IDDA1c 
As shown in Table 2, there also was a progressive increase in IDAA1c that reflected the 
increases in HbA1c values and total daily insulin doses over the course of the study.  
Consequently, the percentage of participants who were in partial remission, as indicated by 
IDAA1c values d9.0, fell from 49% at 3 months to 23% at 12 months and to only 7% at 36 
months, respectively. The rate of decline in C-peptide estimated by the IDAA1c was lower in 
younger participants. 
BMI 
The median (interquartile range) BMI percentile was 50% (14−78%) at the time of 
diagnosis, increased to 69% (44−88%) at 6 months, and then remained relatively constant 
throughout the first three years of T1D (Figure 2).  BMI percentile was inversely associated with 
HbA1c (P<0.001) after adjusting for visit time. 
Severe Hypoglycemia and Diabetic Ketoacidosis 
During the first year of T1D, SH episodes were reported by 2% of participants.  By 24 
and 36 months, the percentages of participants with SH episodes in the prior 12 months were 3% 
and 4%, respectively. The percentage of participants who reported more than one episode of SH 
within the prior 12 months was only 1% at 36 months.  DKA occurred in 1% of participants 
during the first year of T1D, not including episodes at presentation. By 24 and 36 months, the 
percentages of participants with DKA in the prior 12 months increased considerably to 6% and 
6% (Table 2).  Mean HbA1c levels were significantly higher among those with a DKA event 
than those without a DKA event at 12 months, 24 months and 36 months (all p-values<0.001), 
This article is protected by copyright. All rights reserved.
10 
 
with mean A1c 9.4 ± 1.6% vs. 7.8 ± 1.4% (79 ± 17 mmol/mol vs. 61 ± 16 mmol/mol), 9.3 ± 
2.3% vs. 8.0 ± 1.4% (79 ± 25 mmol/mol vs. 64 ± 15 mmol/mol) and 9.3 ± 1.9% vs. 8.3 ± 1.6% 
(79 ± 21 mmol/mol vs. 67 ± 17 mmol/mol) among the DKA vs. no DKA group at 12, 24, and 36 
months respectively. Those participants with a DKA event also had significantly higher IDAA1c 
than those without a DKA event after adjusting for visit time (P=0.002). There was no significant 
difference in either HbA1c or IDAA1c levels between those participants with a SH event and 
those without a SH event after adjusting for visits (P=0.18 and 0.64, respectively). 
Comorbidities diagnosed after initial screening evaluation at diagnosis 
 As shown in Table 3, the cumulative rate for diagnosis of thyroid disease slightly 
increased from 2% during the first year after diagnosis to 3% after three years. While only <1% 
of participants had been diagnosed with psychiatric disorders and 2% had been diagnosed with 
celiac disease during the first year of diabetes, the cumulative event rate of psychiatric disorders 
and celiac disease increased to 2% and 5% respectively after three years of T1D duration.   




An important finding of this study is that the rise in HbA1c levels, increases in total daily 
insulin doses and waning of the partial remission period that were observed between 6 and 12 
months after the diagnosis of T1D in this cohort (5) continued for the next 2 years at slower 
rates, but accompanied with a steep increase in number of episodes of DKA. While the pattern of 
glycemic control changes, namely the timing of nadir HbA1c and the trajectory of rise in HbA1c, 
is similar to those reported during the first 12 months of new onset patients in the DirecNet-
TrialNet Metabolic Control Study (2, 3) and during 24 months of follow-up of the Pediatric 
Onset Study in Europe (4), HbA1c levels were higher in the NeOn Study cohort at each time 
point. These differences may be due to the difference in the frequency and intensity of contact 
with participants in clinical trials versus patients in clinical practice, but could also be due to 
differences in patients who participate in clinical trials versus those who do not. It is noteworthy 
that patients and caregivers responded to the increasing challenges in managing their diabetes by 
maintaining a high frequency of blood glucose monitoring and increasing use of insulin pumps 
over time.  
While c-peptide responses to mixed meal tolerance tests were not measured in the NeOn 
Study, the IDAA1C developed and validated by Mortensen and colleagues, was used as a 
surrogate measure of residual ² -cell function (8). Those investigators demonstrated that an 
IDAA1C value d9.0 predicts peak meal-stimulated c-peptide levels that are almost always >300 
pmol/l. Similar c-peptide responses can be seen in youth with T1D with IDAA1C values 
between 9.0 and 10.0, albeit less frequently. Although there is data supporting the use of 
IDAA1c, the IDAA1c has some limitations. The data were derived from a non-US population 
with a different genetic background. The stimulated C-peptide cut-off level as a measure of 
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residual ² -cell function was even higher than the cut-off level that was used to define absolute 
insulin deficiency in the DCCT cohort (C-peptide <200pmol/L ) despite the fact that, unlike the 
DCCT patient population, subjects younger than 13 years of age were enrolled into the study by 
Mortensen. Hence, the IDAA1c might not be applicable to assess the ² -cell reserve for younger 
patients who tend to have lower C-Peptide levels as compared to older people with new onset 
T1D. Moreover, the DPV partial remission analysis demonstrated younger children are 
significantly less likely to experience partial remission (10). The data points on the regression 
analysis graph published in Mortensen’s paper depict many subjects without partial remission (8) 
who have stimulated C-peptide levels >300pg/mL. The possible underestimation of partial 
remission and a faster rate of increase in older versus younger subjects could be driven by the 
higher insulin dose requirement per kilogram weight commonly observed in adolescent patients 
during puberty (11). Our finding that the proportion of participants with IDDA1c values <9.0 
was as high as 23% at 12 months but fell to 12% and 7% at 24 and 36 months suggests that 
future ² -cell preservation studies may have to be extended to 24-36 months in order to detect 
differences in C-peptide responses between experimental and control groups.  
 It was somewhat surprising that the reported frequency of SH episodes did not increase 
with waning of the partial remission phase during the first 3 years of diabetes treatment. One 
possible explanation is that the IDAA1c might not be a sensitive measure to determine the risk 
for severe hypoglycemia in this patient population. Unlike SH, the number of episodes of DKA 
did rise in parallel to the rise in HbA1c levels, a finding similar to that in pediatric patients with 
longer diabetes duration enrolled in the T1D Exchange Clinic Registry (12).   
T1D Exchange Registry data indicate that youth with T1D have not been spared from the 
epidemic of obesity that afflicts so many non-diabetic children (13). Thus, the initial increase in 
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BMI to >60th percentile at 6 months is likely due to the regain of weight lost prior to the 
diagnosis of diabetes, whereas, the lack of any substantial change in BMI after 6 months is 
evidence against a major effect of insulin treatment itself.  
It is not uncommon for associated autoimmune diseases to develop after the diagnosis of 
T1D, and this explains the increasing prevalence of thyroid and celiac disease over time. The 
increasing prevalence of psychiatric disorders probably represents the increasing age of the 
cohort as participants entered adolescence, increased awareness of mental health issues  (14) as 
well as the longer duration of the disease.  
There are a few limitations of the PDC NeOn Study. The study was not designed as a 
population-based study, since all of the participants enrolled into the study were being followed 
in academic pediatrics diabetes centers within 3 months of diagnosis. While this factor raises a 
concern about representativeness of our findings, the majority of pediatric patients with T1D in 
the U.S. are managed by pediatric diabetologists as common practice, unlike the adult patient 
population whose care is often shared by specialists and primary care givers (15).  Maximum 
amount of possible follow up was incomplete for 29% of the cohort; however, baseline 
characteristics appeared quite similar between those with complete versus incomplete follow up, 
suggesting that this is not a source of bias.  
            The findings of the NeOn Study underscore the importance of maintaining a commitment 
by patients and parents of children with T1D to intensive insulin therapy during the transition 
period out of the partial remission phase in order to keep HbA1c levels within the target range. 
Unfortunately, only about 30% of participants were able achieve this goal after the first 2 years 
of T1D despite their high median income and well educated background.  The percentage of 
pediatric patients who are within target glycemic range has been reported to be even lower, based 
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on a recently published database study (16). Nevertheless, improvements in accuracy and ease of 
use of CGM devices and the introduction of integrated sensor-augmented pump systems provide 
new and relatively untapped opportunities for achieving optimal glycemic control in a larger 
proportion of youth with T1D (17), including those recently diagnosed. As the DCCT has shown, 
getting a larger proportion of patients to target HbA1c levels as early in the course of the disease 
as possible will have long lasting benefits in reducing the risk of future vascular complications 
(1, 18).  
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Table 1: Characteristics at Diagnosis (N=1048a) 
 # % 
Age   
<5 years 199 19% 
5−<12 years 568 54% 
12−<19years 281 27% 
Mean ± SD 9.2 ± 4.2 
Range 0.7 – 18.8 
Gender   
Female 513 49% 
Race/Ethnicity   
Non-Hispanic White 671 65% 
Hispanic or Latino 216 21% 
Black/African American 81 8% 
Other/Multiple Race 59 6% 
Health Insurance   
Private  681 66% 
Children’s Health Plan or Other Government 302 29% 
Military 19 2% 
None 23 2% 
Parent Education   
High School or Less 291 34% 
This article is protected by copyright. All rights reserved.
21 
 
Associate Degree 121 14% 
BS/BA 245 29% 
MS/MA/Professional Degree 202 24% 
Family Income   
<$25,000 101 14% 
$25,000-$49,999 133 19% 
$50,000-$74,999 112 16% 
$75,000-$99,999 101 14% 
e$100,000 255 36% 
a. Number of participants with missing data: race/ethnicity (21), health insurance (23), parent education (189), and 
family income (346). 
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Table 2: Clinical Characteristics by Completed Follow-up Visit 
  Diagnosis 3 Months 6 Months 12 Months 24 Months 36 Months 
 N=1048b N=841b N=838b N=897b N=822b N=607b 
Pump Use 12 (1%) 76 (9%) 141 (17%) 309 (34%) 376 (46%) 293 (48%) 
  N=784b N=786b N=847b N=481b N=356b 
CGM Use NA 2% 3% 2% 4% 4% 
  N=507b N=495b N=517b N=417b N=322b 
Self Blood Glucose 
Monitoring (# tests 
/ day)  
median (IQR) 
NA 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 7) 5 (4, 7) 
 
N=980b N=788b N=789b N=859b N=789b N=579b 
HbA1c  
(% [mmol/mol]) 
mean ± SD  
 
11.5 ± 2.3 
[102 ± 25] 
7.2 ± 1.1 
[55 ± 12] 
7.3 ± 1.4 
[56 ± 15] 
7.8 ± 1.5 
[62 ± 16] 
8.1 ± 1.4 
[65 ± 16] 
8.4 ± 1.6 
[68 ± 18] 
Age <5 years 
10.5 ± 2.0 
[91 ± 21] 
7.8 ± 1.1 
[62 ± 12] 
7.9 ± 1.2 
[62 ± 14] 
7.9 ± 1.1 
[62 ± 12] 
7.9 ± 1.0 
[63 ± 11] 
8.0 ± 1.2 
[64 ± 13] 
5−<12 years 
11.5 ± 2.3 
[102 ± 25] 
7.1 ± 1.0 
[54 ± 11] 
7.2 ± 1.2 
[55 ± 13] 
7.8 ± 1.3 
[62 ± 14] 
8.1 ± 1.4 
[65 ± 15] 
8.4 ± 1.5 
[68 ± 17] 
12−<19 years 
12.1 ± 2.4 
[109 ± 27] 
7.0 ± 1.2 
[53 ± 13] 
7.0 ± 1.7 
[53 ± 18] 
7.7 ± 2.0 
[61 ± 21] 
8.1 ± 1.8 
[65 ± 20] 
8.6 ± 2.0 
[71 ± 22] 





3% 61% 61% 45% 34% 30% 
  N=747b N=611b N=708b N=741b N=539b 
HbA1c Change (% 
[mmol/mol]) 
mean ± SD  
 
NA 
-4.3 ± 2.5 
[-47 ± 28] 
+0.1 ± 1.1 
[+1 ± 12] 
+0.5 ± 1.2 
[+5 ± 13] 
+0.3 ± 1.1 
[+4 ± 12] 
+0.2 ± 1.1 
[+2 ± 12] 
  N=691b N=713b N=795b N=442b N=316b 
Total Insulin 
(u/day/kg) 
mean ± SD  
NA 0.5 ± 0.3 0.5 ± 0.3 0.7 ± 0.3 0.8 ± 0.4 1.0 ± 0.6 
Basal  NA 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.2 
Bolus  NA 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.4 0.6 ± 0.5 
  N=669b N=678b N=767b N=421b N=296b 
IDAA1c (%)  
mean ± SD  
NA 9.3 ± 1.8 9.4 ± 2.1 10.5 ± 2.2 11.3 ± 2.4 12.2 ± 2.9 
IDAA1cd9.0% NA 49% 48% 23% 12% 7% 
Age<5 years NA 35% 31% 22% 13% 10% 
5−<12 years NA 52% 52% 21% 11% 3% 
12−<19 years NA 53% 54% 28% 11% 14% 
   N=473b N=581b N=376b N=188b 
IDAA1c Change NA NA +0.2 ± 1.6 +0.9 ± 1.7 +0.9 ± 2.0 +1.2 ± 2.8 
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(%) mean ± SD  
    N=1044b N=727b N=584b 
SH in prior yeara NA NA NA 2% 3% 4% 
# SH events >1 in 
prior yeara 
NA NA NA <1% <1% 1% 
DKA reported in 
prior yeara 
NA NA NA 1%c 6% 6% 
# DKA events >1 in 
prior yeara 
NA NA NA <1%c 1% 1% 
a. Participant/parent was asked at the visit whether an event had occurred in the previous 12 months. 
b. N varies due to missing data at the particular time point. 
c. DKA events at diagnosis were excluded.
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Table 3 Comorbidities after T1D Diagnosis (N=1044a) 
Diabetes Duration, 
years 





N Cumulative Event 
Rate 
1 16 2% 19 2% 7 <1% 
2 7 2% 14 3% 10 2% 
3 5 3% 11 5% 3 2% 
Total 28  44  20  
a- Excludes 4 participants with no visit available after enrollment 
b- Includes Graves’ disease, Hashimoto’s and any other thyroiditis 
c- Includes bipolar, anxiety, depression, disruptive behavior, central pain syndrome  
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Supplemental Table 1: Comparing Characteristics of 3-Year Completers and Non-
completers 




Age   
<5 years 108 (18%) 91 (21%) 
5−<12 years 356 (59%) 212 (48%) 
12−<19years 143 (24%) 138 (31%) 
Mean ± SD 9.0 ± 3.9 9.5 ± 4.6 
Range 0.8 – 18.2 0.7 – 18.8 
Gender   
Female 305 (50%) 208 (47%) 
Race/Ethnicity   
Non-Hispanic White 387 (65%) 284 (66%) 
Hispanic or Latino 122 (21%) 94 (22%) 
Black/African American 45 (8%) 36 (8%) 
Other/Multiple Race 40 (7%) 19 (4%) 
Health Insurance   
Private  396 (66%) 285 (67%) 
Children’s Health Plan or Other 
Government 
176 (29%) 126 (29%) 
Military 13 (2%) 6 (1%) 
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None 12 (2%) 11 (3%) 
Parent Education   
High School or Less 164 (33%) 127 (35%) 
Associate Degree 66 (13%) 55 (15%) 
BS/BA 142 (29%) 103 (28%) 
MS/MA/Professional Degree 119 (24%) 83 (23%) 
Family Income   
<$25,000 61 (15%) 40 (14%) 
$25,000-$49,999 71 (17%) 62 (21%) 
$50,000-$74,999 65 (16%) 47 (16%) 
$75,000-$99,999 64 (16%) 37 (13%) 
e$100,000 146 (36%) 109 (37%) 
a. Completers defined as participants who had visit within ±3 months of 36-month target date. 
b. Number of participants with missing data (completers/non-completers): race/ethnicity (13/8), health insurance 
(10/13), parent education (116/73), and family income (200/146).   
This article is protected by copyright. All rights reserved.
 28 
 
Supplemental Table 2: Clinical Characteristics among 3-Year Completersa 
  Diagnosis 3 Months 6 Months 12 Months 24 Months 36 Months 
 N=607c N=490c N=520c N=571c N=565c N=607c 
Pump Use <1% 7% 15% 34% 45% 48% 
  N=452c N=485c N=538c N=354c N=356c 
CGM Use NA 1% 2% 2% 4% 4% 
  N=314c N=323c N=345c N=304c N=322c 
Self Blood Glucose 
Monitoring (# tests 
/ day)  
median (IQR) 
NA 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 7) 5 (4, 7) 
 
N=578c N=462c N=491c N=551c N=546c N=579c 
HbA1c  
(% [mmol/mol]) 
mean ± SD  
 
11.5 ±2.4 
[102 ± 26] 
7.2 ± 1.1 
[55 ± 12] 
7.2 ±1.3 
[55 ± 14] 
7.7 ±1.4 
[61 ± 15] 
8.1 ± 1.4 
[65 ± 15] 
8.4 ± 1.6 
[68 ± 18] 
Age <5 years 
10.5 ± 2.1 
[91 ± 23] 
7.8 ± 1.2 
[62 ± 13] 
7.9 ± 1.2 
[62 ± 13] 
7.9 ± 1.1 
[63 ± 12] 
8.0 ± 1.0 
[64 ± 11] 
8.0 ± 1.2 
[64 ± 13] 
5−<12 years 
11.6 ± 2.3 
[103 ± 25] 
7.1 ± 1.0 
[54 ± 11] 
7.2 ± 1.2 
[55 ± 14] 
7.7 ± 1.3 
[61 ± 14] 
8.1 ± 1.3 
[65 ± 15] 
8.4 ± 1.5 
[68 ± 17] 
12−<19 years 
12.2 ± 2.4 
[110 ± 26] 
6.8 ± 1.1 
[51 ± 12] 
6.7 ± 1.3 
[50 ± 14] 
7.5 ± 1.7 
[58 ± 18] 
8.0 ± 1.7 
[64 ± 18] 
8.6 ± 2.0 
[71 ± 22] 





3% 64% 64% 47% 32% 30% 
  N=447c N=374c N=461c N=514c N=539c 
HbA1c Change  
(% [mmol/mol]) 
mean ± SD  
 
NA 
-4.3 ± 2.7 
[-47 ± 29] 
+0.1 ± 1.0 
[+1 ± 11] 
+0.4 ± 1.2 
[+5 ± 13] 
+0.3 ± 1.1 
[+4 ± 12] 
+0.2 ± 1.1 
[+2 ± 12] 
  N=403c N=448c N=511c N=327c N=316c 
Total Insulin 
(u/day/kg)  
mean ± SD 
NA 0.5 ± 0.3 0.5 ± 0.3 0.6 ± 0.3 0.8 ± 0.4 1.0 ± 0.6 
Basal  NA 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 
Bolus  NA 0.2 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.3 0.6 ± 0.5 
  N=390c N=426c N=494c N=317c N=296c 
IDAA1c (%) 
mean ± SD  
NA 9.3 ± 1.7 9.3 ± 1.9 10.4 ± 2.1 11.2 ± 2.2 12.2 ± 2.9 
IDAA1cd9.0% NA 50% 50% 23% 12% 7% 
Age <5 years NA 35% 29% 20% 16% 10% 
5−<12 years NA 50% 54% 23% 10% 3% 
12−<19 years NA 63% 58% 28% 11% 14% 
   N=291c N=378c N=285c N=188c 
IDAA1c Change NA NA +0.2 ± 1.4 +1.0 ± 1.6 +0.9 ± 1.7 +1.2 ± 2.8 
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(%) mean ± SD  
    N=607c N=462c N=532c 
SH in prior yearb NA NA NA 2% 4% 4% 
# SH events >1 in 
prior yearb 
NA NA NA <1% <1% 1% 
DKA reported in 
prior yearb 
NA NA NA 1%d 5% 6% 
# DKA events >1 
in prior yearb 
NA NA NA 0% 1% 1% 
a – 3-year completer is defined as participants who had visit within ±3 months of 36-month target date.  
b – Participant/parent was asked at the visit whether an event had occurred in the previous 12 months. 
c – N varies due to missing data at the particular time point. 
d – DKA events at diagnosis were excluded.




Figure 1: HbA1c by T1D Duration 
The bottom and the top of each box plot denote the 25th and 75th percentiles.  Horizontal line 
inside each box plot denotes the median, and the dot denotes the mean. 
Figure 2: BMI Percentile by T1D Duration 
The bottom and the top of each box plot denote the 25th and 75th percentiles.  Horizontal line 
inside each box denotes the median, and the dot denotes the mean. 
Figure 3: Scatter Plots for HbA1c at Different Visits 
A) HbA1c at 24 months vs. 12 months; B) HbA1c at 36 months vs. 12 months; C) HbA1c at 36 
months vs. 24 months.  
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N=625 N=763 N=779 N=871 N=481 N=351
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